How many investments has Ampersand made?

Ampersand has 69 tracked investments, 3 of which have exited via acquisition or IPO, including 1 dated in the last 24 months.

What stage does Ampersand invest at?

Ampersand invests at the Growth stage.

What sectors does Ampersand focus on?

Ampersand focuses on Biotech, Healthtech, Medical Devices.

Where is Ampersand located?

Ampersand is headquartered in Boston, US.

Who does Ampersand co-invest with?

Ampersand most often shares deals with ARCH Venture Partners, BioGenerator Ventures, Blumberg Capital, among 34 tracked co-investors.

Ampersand

Private equity

Boston · Growth · 36 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Ampersand

2,457 people in our graph share verified history with the Ampersand team — schools, employers, funds. One of them is your warm intro.

Niki Pezeshkiunlockedknows Natalia C. Anderson · together at Summit Partners (overlapped)

×2knows the team · via Morgan Stanley Smith Barney

knows the team · via Harvard University

knows the team · via Summit Partners

knows the team · via UBS Investment Bank, Global Healthcare Group

knows the team · via Harvard Business School

✨ Fox Verdict

Investment thesis

Ampersand focuses on minority and majority equity investments in growth-oriented life sciences and healthcare companies, targeting sub-segments where the firm holds deep industry experience. It partners closely with founders and management teams to drive both organic and inorganic growth, adding value through board-level engagement while management retains day-to-day control. Capital is used for business expansion and growth equity, recapitalizations and shareholder liquidity, management buyouts, and corporate divestitures. Founded in 1988, the firm has a portfolio of more than 80 companies and roughly $3 billion in assets under management, and is currently investing out of its eleventh fund.

Invests inBiotech Healthtech Medical Devices Boston Europe United States

Source: firm website, verified Sep 15, 2026.

Stage

Growth

Boston, MA, US

Instruments

Equity

Founded

1988

AUM

$3.1B

Tracked investments

Team · 36 people

from the firm's website & curated

David Q. Anderson· General Partner· Bostonin

David Anderson joined Ampersand in 2010. He previously spent six years at Covington Associates, a specialty investment bank focused on middle-market healthcare M&A, and five years before that as a consultant at Boston Healthcare Associates. He holds a B.Sc. from the University of Aberdeen, a Ph.D. in Immunology from the University of Sheffield, and an M.B.A. from Babson College.

Eric B. Lev· General Partner

Eric B. Lev is a General Partner at Ampersand, which he joined in 2013, with more than 22 years of experience in middle-market healthcare investing. He was previously a founding member of the investment team at Water Street Healthcare Partners for seven years, and earlier worked at Beckman Coulter and One Equity Partners. He holds a B.A. in Economics from Northwestern University and an M.B.A. from the University of Chicago.

Richard A. Charpie· Founder· Boston

Rick Charpie has over 35 years of private equity experience and founded Ampersand in 1988 through a spinoff from PaineWebber. He has served as a director of more than 35 companies and chaired more than ten. He holds an M.S. in Physics and a Ph.D. in Economics and Finance, both from MIT.

Marina Pellón-Consunji· Partner· Bostonin

Marina Pellón-Consunji joined Ampersand in 2013. She previously worked as an Associate Director in Healthcare Investment Banking at UBS, handling leveraged buyouts, M&A, and debt and equity financings for middle-market healthcare companies. She holds a B.A. with Honors in Biological Chemistry and International Relations from Wellesley College and worked in biochemistry laboratories at Harvard Medical School after graduating.

Melanie M. Fan· Partner· Bostonin

Melanie M. Fan is a Partner at Ampersand, which she joined in 2018. She previously worked at Frazier Healthcare, a middle-market private equity firm, and earlier at UBS Investment Bank, where she focused on leveraged buyouts, M&A, and debt and equity financings for middle-market healthcare companies. She holds a B.S. in Economics and Statistics from Duke and an M.B.A. in Health Care Management from Wharton.

Hidde Van Kerckhoven· Principal· Amsterdamin

Hidde Van Kerckhoven is a Principal at Ampersand Capital Partners, which he joined in 2022. He previously worked on the healthcare investment team at Gimv, where he was involved in platform acquisitions and add-ons across healthcare services and life sciences, and earlier was an associate at The Riverside Company in Brussels. He holds an MSc in Finance from the Antwerp Management School.

Aditya V. Goel· Associate· Boston

Aditya (Adi) Goel joined Ampersand in 2025 as an Associate. He previously worked as an Investment Analyst at Bracebridge Capital, investing across the capital structure in life sciences companies, and before that as a Senior Analyst at ClearView Healthcare Partners advising on biopharma strategy. He holds a B.A. in Molecular and Cell Biology from UC Berkeley and an M.B.A. in Healthcare Management and Finance from Wharton.

Benoit P. Bouche· Operating Partner· Londonin

Benoit P. Bouche joined Ampersand as an Operating Partner in 2022 and chairs the board of P95. His career spans nearly 40 years in healthcare businesses as an entrepreneur, investor, advisor, and board member, with a focus on the pharmaceutical outsourcing industry. He was previously President and CEO of Nexelis, an immunology-focused lab and former Ampersand portfolio company acquired by IQVIA, and holds a PharmD (1984) and a Ph.D. in Pharmaceutical Sciences/Biotechnology (1986), along with completion of Harvard Business School's Advanced Management Program (2002).

Cole S. Aldrich· Senior Associate· Boston

Cole S. Aldrich joined Ampersand in 2024. He previously worked as an Associate at Nautic Partners, a middle market private equity firm, and earlier as an Analyst in the Healthcare Services group at Guggenheim Partners. He earned a B.A. in Economics from the University of Virginia.

Dean D. Schauer· Operating Partner· Amsterdam

Elias J. Laimboeck· Senior Associate· London

Elias J. Laimboeck joined Ampersand in 2026. He was previously a Senior Associate at Trilantic Europe, a pan-European middle-market private equity firm, where he focused on healthcare and industrials investments, and earlier an Associate in J.P. Morgan's Consumer & Retail investment banking group in London. He holds an M.Sc. in International Finance from HEC Paris and an M.A. (Hons) in Economics and Chinese from the University of Edinburgh.

Emanuele M. Delfino· Associate· Londonin

Emanuele M. Delfino joined Ampersand in 2025. He previously worked as an Investment Banking Analyst in the Healthcare Group at Houlihan Lokey, focusing on leveraged buyouts and M&A for middle-market healthcare companies. He earned an MSc in Finance and a BSc in International Economics and Finance from Bocconi University.

Frank R. Witney· Operating Partner

Henry Dubina· Executive Advisor· Boston

Henry Dubina joined Ampersand as an Executive Advisor in 2021 and serves as a consultant and board member for technology and software companies in the biopharmaceutical industry. He previously was President of Mettler-Toledo AutoChem from 1999, and earlier founded and grew Applied Systems Inc. (ASI), a provider of in-situ FTIR systems (ReactIR), which Mettler-Toledo International acquired in 1999. He also served as President of Leica USA Inc. and began his career at IBM in sales and marketing management roles. He holds a B.S. in Chemistry from the University of Illinois.

Isabel S. Brooks· Senior Associate· Londonin

Isabel S. Brooks joined Ampersand in 2026. She was previously an Associate at the middle-market private equity firm Astorg MidCap, where she spent two years working on healthcare buyouts across the UK and Europe in pharma services, medtech, and life sciences tools, and earlier worked as a Consultant at Candesic, a healthcare and life sciences commercial due diligence firm. She holds a B.Sc. in Biomedical Sciences from Durham University and an M.Sc. in Integrated Immunology from the University of Oxford.

Jay S. Ray· Operating Partner· Boston

Jean Qiu· Executive Advisor

Jonathan Hunt· Executive Advisor· Boston

Jonathan Hunt joined Ampersand as an Executive Advisor in 2026. He was previously CEO and Managing Director of Syngene International, a global contract research, development and manufacturing organization, from 2016 to 2025, and earlier spent 17 years at AstraZeneca and Astra in senior leadership roles including President of AstraZeneca Austria, President of AstraZeneca India, and Head of Investor Relations. He holds an MBA from Durham University and a B.A. (Hons) in Business and Economics from the University of Sheffield, with executive education from MIT Sloan.

Julie F. Giles· Controller· Boston

Julie F. Giles joined Ampersand's accounting and finance team in 2003. She previously held accounting positions at PHT Corporation and Enermetrix. She earned a B.S. in Business Administration with a concentration in Accounting from Lasell University and an M.B.A. from Bentley University.

Justin K. Choi· Associate· Boston

Justin K. Choi joined Ampersand as an Associate in 2025. He previously worked as an Associate in the Healthcare Services group at Jefferies in New York and, before that, as an Analyst at Leerink Partners. He earned a B.S. in Finance with highest honors from Lehigh University.

Kristine C. Austin· Executive Assistant· Boston

Kristine C. Austin has been with Ampersand since 1998, serving as an Executive Assistant. Before joining the firm, she held Office Manager and Executive Administrative Assistant roles at Magellan Public Solutions and Integrated Health Strategies. She is a Commonwealth of Massachusetts Notary.

Madeline Brown-Scherer· Manager, Business Development· Boston

Madeline Brown-Scherer works in business development at Ampersand, having first joined in 2022 and returned in 2026. From 2025 to 2026 she was a Business Development Manager on the Healthcare team at THL, and she previously interned at the Pennsylvania Department of Health. She holds a B.A. in Biology from Johns Hopkins University.

Mark R. Bamforth· Executive Advisor

Mark R. Bamforth joined Ampersand as an Operating Partner in 2018 and became an Executive Advisor in 2023. He founded several contract development and manufacturing organizations, including Brammer Bio (cell and gene therapy, sold to Thermo Fisher Scientific in 2019), Arranta Bio (mRNA, sold to Recipharm), and Gallus BioPharmaceuticals (sold to DPx Holdings/Patheon in 2014), and earlier spent 22 years at Genzyme Corp. running global operations and its pharmaceutical CMO business. He holds a B.S. in Chemical Engineering from Strathclyde University and an M.B.A. from Henley Management College.

Maxwell R. Keeley· Vice President· Amsterdam

Maxwell R. Keeley joined Ampersand in 2020. He previously worked as an Analyst at TM Capital, a middle-market investment bank, where he concentrated on healthcare M&A transactions. He earned a B.A. in Economics from Amherst College.

Natalia C. Anderson· Senior Manager, Compliance· Bostonin

Natalia C. Anderson joined Ampersand in 2020, working in compliance. She previously spent five years in compliance roles at Summit Partners. She earned a B.S. in Business Administration and Political Science from Northeastern University and holds the Investment Adviser Certified Compliance Professional (IACCP) designation from the Investment Advisor Association.

Nicolas S. Gianelli· Senior Associate· Bostonin

Nic Gianelli joined Ampersand in 2022. He previously worked as a Senior Analyst at Crosstree Capital, a middle-market investment bank, where he concentrated on healthcare M&A, and before that held a Corporate Strategy and M&A role at Philips Healthcare. He earned a B.S. in Biomedical Engineering from the University of Connecticut.

Olivia M. Ciano· Fund Accountant· Bostonin

Olivia M. Ciano joined Ampersand in 2025 as a Fund Accountant. She previously worked as a Senior Associate in the Assurance practice at PwC. She holds a B.S. in Business Administration with a concentration in Accounting and Finance from the University of Pittsburgh and is a CPA.

Peter Li· CEO of Nexcelom (joined 2006)· Boston

Dr. Peter Li joined Nexcelom Biosciences as CEO in 2006. Alongside founder Dr. Jean Qiu, he led the company's growth over more than a decade, building it into a maker of cell analysis instruments and reagents. In 2017, the company partnered with Ampersand Capital Partners to support its expansion.

Stefan Beyer· Executive Advisor

Stefan Beyer joined Ampersand as an Executive Advisor in 2024, drawing on more than 20 years in leadership and business development across the life sciences sector. He previously served as CEO and later President of Vibalogics, a CDMO focused on oncolytic viral vectors and viral vector vaccines that was acquired by Recipharm in 2022, and has experience converting family-owned businesses into investor-backed growth companies. He holds a Ph.D. in biology and biotechnology with a focus on the molecular biology of natural product-producing microorganisms.

Steve Favaloro· Executive Advisor· Boston

Steve Favaloro is a biotech executive, board member, and investor who serves as an executive advisor at Ampersand Capital Partners. He is Chairman and CEO of Genezen, a gene and cell therapy CDMO, and previously held CFO roles at Arbor Biotechnologies, Arranta Bio (acquired by Recipharm in 2022), and Brammer Bio (sold to Thermo Fisher Scientific in 2019), along with earlier finance roles at MilliporeSigma, Merck KGaA, and Bruker Corporation. He holds an MBA and MS from the Carroll School of Management at Boston College and a BA in Economics from Boston College.

Steven J. Chang· Finance Manager· Boston

Steven J. Chang joined Ampersand in 2025 as Finance Manager. He previously spent five years in corporate financial planning and analysis at publicly held biopharmaceutical companies, and earlier oversaw SEC financial reporting at TESARO, an oncology biopharmaceutical company, until its acquisition by GlaxoSmithKline; he began his career at Deloitte in Audit & Assurance. He holds a B.S. from Case Western Reserve University and an M.S. from Northeastern University, both in Accounting, and is a CPA in Massachusetts.

Steven M. Dale· Senior Manager, Accounting· Boston

Steven M. Dale joined Ampersand in 2018. He previously worked as an Audit Supervisor in the Financial Services practice at RSM. He holds a B.S. and an M.S. in Accounting from Penn State University and is a C.P.A.

Stuart A. Auerbach· Advisory Partner· New York, New York, United Statesin

Stuart A. Auerbach joined Ampersand in 1991 and served as a General Partner for over 15 years, working with an investor team that developed more than a dozen industrial and healthcare businesses. Earlier in his career, he spent three years consulting at Bain and Company and five years in manufacturing and engineering at Lever Brothers. He holds a B.S. in Chemical Engineering from Columbia and an M.B.A. from Harvard Business School.

Thomas de Jager· Vice President, Business Development· Bostonin

Thomas de Jager first worked at Ampersand as an Associate from 2005 to 2008, evaluating investment opportunities and supporting the firm's DOR sourcing efforts. Between 2008 and 2010 he founded Savannah Acquisitions, an M&A advisory firm focused on buy-side transactions, before rejoining Ampersand in 2011 to coordinate the DOR program. He holds a B.A. in Economics from the University of Pretoria and an M.B.A. from Pace University.

K.C. R. Creasy· Fund Accountantin

K.C. R. Creasy is a Fund Accountant at Ampersand Capital Partners and a licensed CPA in Massachusetts. Creasy holds a BSBA in Accounting and Finance from the University of Pittsburgh, along with a certificate in Business Analytics.

Neale Butler· Senior Manager, Compliance· Charlotte, North Carolina, United Statesin

What they invest in

from 48 of 71 portfolio companies

Healthtech ×35Biotech ×34Medical Devices ×30Advanced Manufacturing ×19Deep Tech ×16Digital Health ×11Enterprise Software ×9New Materials ×6

HQs:United States×29United Kingdom×3Belgium×2Netherlands×2Germany×1Ireland×1

Who they back

founder profiles across 10 portfolio companies

70%

solo founders

7 of 10 mapped founding teams

Founding team size:solo founder×72 founders×3

Investments · 71 tracked

founders shown can be your intro path

By year:2025 · 1 2023 · 1 2022 · 2 2021 · 26 dated

ANI Pharmaceuticalsanipharmaceuticals.com inNASDAQ: ANIP

ANI Pharmaceuticals is a generic and specialty pharmaceutical company that develops, manufactures, and distributes prescription drugs across multiple therapeutic areas including generics, rare diseases, and established branded products.

BiotechHealthtechMedical Devices

Nikhil Lalwani(President and Chief Executive Officer)inMuthusamy Shanmugam(Head of R&D and Chief Operating Officer of NJ Operations)

Co-investorsThe Argentum Group

Perkinelmerperkinelmer.com in 𝕏NYSE: RVTYSep 2021Acquired

PerkinElmer is a scientific instrument and technology company that provides analytical tools and services for research, diagnostics, and life sciences applications.

BiotechDeep TechEnterprise SoftwareHealthtechMedical DevicesWaltham, US

Richard Scott PerkinJames M. Mock(Executive Officer)Andrew Okun(Executive Officer)inJoel S. Goldberg(Executive Officer)Prahlad Singh(Executive Officer, Director)inTajinder Vohra(Executive Officer)in

Co-investorsARCH Venture Partners Partners for Growth Partners for Growth (PFG)

Adaptas

Laboratory instrumentation CDMO, originally a supplier of mass spectrometry components, scaled globally via acquisitions and later sold to IMI.

Adaptas Solutionsadaptas.com

Admerahealthadmerahealth.com

AIT Biosciencenexelis.com in

IQVIA Laboratories provides central laboratory and specialty biomarker services for drug discovery and development, serving pharmaceutical sponsors and clinical trial sites.

BiotechHealthtechMedical DevicesIndianapolis, US

Ronald E. Shoup(Executive Officer, Director)Michael Evans(Executive Officer, Director)Teresa A. Pascarelli(Executive Officer, Director)Terry J. Spartz(Executive Officer, Director)

BoardR. J. McConnell(Director)John H. Barnard(Director)

Co-investorsElevate Ventures

Alcamialcami.com in 𝕏

Alcaminowalcaminow.com in 𝕏

Alpcoalpco.com

AnaBiosanabios.com in 𝕏May 2022

AnaBios generates predictive human data for pharmaceutical drug development, using authentic human cells and tissues from healthy and diseased donors to assess drug efficacy and toxicity before clinical trials.

BiotechDeep TechHealthtechSan Diego, US

Andre Ghetti(Chief Executive Officer)inRichard F. Erdman(Director)Paul Miller(Executive Officer)Jack Reynolds(Executive Officer, Director)Peter Crowley(Director)George Goldsmith(Director)

Co-investorsKeiretsu Forum Tech Coast Angels

Avidbioavidbio.com in

Avid Bio provides development and manufacturing services for biologics programs, offering integrated support from early-stage development through commercialization.

Advanced ManufacturingBiotechDeep TechEnterprise SoftwareHealthtechTustin, US

Co-investorsGHO Capital Partners

Bakodxbakodx.com in 𝕏

Bako Diagnostics provides laboratory diagnostic services specialized in testing nail, skin, wound, soft tissue, and bone samples from the lower extremity for the podiatric medical community.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Dr. W. L. Bakotic

Balchembalchem.com

Beacon Intelligencebeacon-intelligence.com in 𝕏

Beacon provides a comprehensive drug development database for the life sciences industry, offering detailed intelligence on molecules, therapeutic targets, and companies across various disease areas and modalities.

BiotechData & InfrastructureEnterprise SoftwareHealthtech

Rob(Leader, Beacon and Intelligence business)

Biologosbiologos.com in 𝕏

Biologos is a GMP-certified manufacturer of custom cell culture media, buffers, and reagents for biopharmaceutical and research customers.

Advanced ManufacturingBiotechDeep TechMedical Devices

Biosynthbiosynth.com

Bioventusbioventus.com in 𝕏

Bioventus develops and markets medical devices for active healing, including pain management, restorative therapies, and surgical solutions that aim to enhance the body's natural healing processes and reduce the need for invasive procedures.

BiotechDeep TechHealthtechMedical DevicesDurham, US

Robert Claypoole(Chief Executive Officer)

Co-investorsAlta Partners Essex Woodlands Healthcare Partners

Brammer Bio

Cambrexcambrex.com in

Cambrex provides pharmaceutical supply chain management and manufacturing services focused on supply chain resilience through dual sourcing and contingency planning to ensure reliable product delivery during disruptions.

Advanced ManufacturingBiotechEnterprise SoftwareHealthtechEast Rutherford, US

Canopy Biosciencescanopybiosciences.com in 𝕏

Canopy Biosciences (Bruker Spatial Biology) develops spatial biology instruments and assays for analyzing gene expression, RNA, and proteins in tissue samples.

BiotechHealthtechMedical DevicesSaint Louis, US

EDWARD WEINSTEIN(President, Chief Executive Officer and Manager)CRYSTAL WINKELER(Chief Operating Officer)CHARLES BOLTEN(Director)DAVID KINGSLEY(Director)

Board DAVID SMOLLER(Director)in

Co-investorsBioGenerator Ventures

Confluentmedicalconfluentmedical.com in 𝕏

Confluent Medical Technologies is a contract manufacturer of medical devices that supports companies in designing and producing healthcare products.

Advanced ManufacturingEnterprise SoftwareMedical DevicesNew Materials

Dean SchauerinDoug HutchisonMatt Eckl(Chief Financial Officer)inTom TestainBrian AdcockinRichard Brown

Crivercriver.com

Curiaglobalcuriaglobal.com in

Curia provides R&D and manufacturing services to help clients address complex scientific and production challenges.

Advanced ManufacturingBiotechDeep TechEnterprise SoftwareHealthtechAlbany, US

Thomas E. D'Ambra, Ph.D.(Co-founder)

Curteccurtec.com in

CurTec manufactures high performance plastic packaging — drums, pails, and jars — for storing and transporting critical materials such as active pharmaceutical ingredients, specialty chemicals, and precious metals.

Advanced ManufacturingCircular EconomyNew Materials

Dynextechnologiesdynextechnologies.com in

DYNEX Technologies develops and manufactures automated ELISA and chemiluminescence microplate instruments for clinical and diagnostic laboratories.

HealthtechMedical Devices

Co-investorsTelegraph Hill Partners

Eurofins Viracoreurofins-viracor.com in 𝕏

Eurofins Viracor is a clinical laboratory that develops and delivers diagnostic tests for infectious diseases, cellular function disorders, oncology, and transplant rejection monitoring.

BiotechDigital HealthHealthtechMedical Devices

Michelle Altrich(President)in

Flagshipbioflagshipbio.com in 𝕏

Flagship Biosciences is a CLIA-certified, CAP-accredited spatial biology and biomarker services company that combines AI-powered tissue analysis with scientific consultation.

AI & Machine LearningBiotechDigital HealthHealthtechWestminster, US

Dean Northey(Executive Officer)G. David Young(Executive Officer, Director, Promoter)Trevor Johnson(Executive Officer, Director, Promoter)Nancy A. Gillett(Director)Gary M. Clark(Director)Gregory K. Tucker(Director)

Freudenbergmedicalfreudenbergmedical.com in

Freudenberg Medical is a contract medical device manufacturing partner offering vertically integrated capabilities including minimally invasive solutions, precision molding, extrusions, and specialized coatings for medical device and pharmaceutical companies.

Advanced ManufacturingHealthtechMedical DevicesKaiserslautern, DE

Gannet BioChemgannetbiochem.com in

Gannet BioChem operates FDA-inspected cGMP manufacturing facilities in Alabama for polymer reagents, activated PEG compounds, and bulk pharmaceutical chemicals, serving research, clinical, and commercial programs at scales from grams to commercial volumes.

Advanced ManufacturingBiotechDeep TechNew MaterialsHuntsville, US

Nick Shackleyin

Gendxgendx.com in 𝕏

GenDx develops molecular diagnostic reagents, software, and services for transplant patient outcomes.

BiotechDigital HealthHealthtechMedical DevicesUtrecht, NL

Erik Rozemuller PhD(Co-founder)Wietse Mulder PhD(Co-founder)

Genewizgenewiz.com

GENEWIZ provides sequencing, synthesis, and molecular biology services for research, clinical, and therapeutic applications, serving academic institutions, biotech companies, and pharmaceutical organizations.

BiotechDeep TechHealthtechMedical Devices

Amy Liao, PhD(Founder)in

Genezengenezen.com

Gyrosproteintechnologiesgyrosproteintechnologies.com in 𝕏

Gyros Protein Technologies develops the Gyrolab platform, an immunoassay solution for bioprocess applications in the biotechnology industry.

BiotechDeep TechHardwareHealthtechMedical Devices

Hydrolixc212.net

Co-investorsA-Rod Corp AllCloud Altitude Accelerator Band of Angels Blumberg Capital Boulder Ventures+10 more

Iconplciconplc.com in 𝕏

ICON plc is a global Contract Research Organization providing consulting and outsourced development services to pharmaceutical, biotechnology, medical device, and government organizations to accelerate drug and device development.

AI & Machine LearningBiotechDigital HealthEnterprise SoftwareHealthtechMedical DevicesDublin, IE

Interpaceinterpace.com in

Interpace Biosciences provides molecular diagnostic tests for the early diagnosis and treatment of cancer, with a focus on risk-stratifying indeterminate thyroid nodules through genetic and mutational analysis.

BiotechDigital HealthHealthtechMedical DevicesPittsburgh, US

Ionnlionnl.com in

A contract manufacturer offering turnkey supplement and nutraceutical production services, including capsules, gummy vitamins, tablets, powders, and liquid formulations for consumer brands.

Advanced ManufacturingConsumerFoodTechHealthtechFlorida, US

Iuvobioscienceiuvobioscience.com in

iuvo is a contract research organization (CRO) focused exclusively on ophthalmology, managing clinical trials across anterior and posterior eye segments from protocol development through regulatory submission.

BiotechHealthtechMedical Devices

Juliusclinicaljuliusclinical.com in 𝕏

P95 Julius Clinical is a contract research organization that conducts clinical trials and real-world evidence programs for biotech and pharmaceutical companies, with expertise in neuroscience, infectious diseases, vaccines, and cardiovascular and metabolic diseases.

BiotechDigital HealthHealthtechMedical DevicesUtrecht, NL

Kedrionkedrion.com

Leincoleinco.com in 𝕏

Leinco Technologies manufactures antibodies and proteins, offering both large- and small-scale IVD antibody and protein production along with CDMO services for scientists in life sciences discovery, biopharmaceutical, and diagnostics segments.

BiotechHealthtechMedical DevicesSt. Louis, US

W. Pat Leinert Sr.(Founder)in

Lexington Medical, Inclexington-med.com inApr 2025

Lexington Medical is a surgical stapling company that develops endostapler devices for surgical procedures, including its AEON Endostapler used in thoracic surgery such as lung volume reduction.

Advanced ManufacturingHealthtechMedical DevicesBedford, US

Leon Amariglio(Founder & CEO)Jameson Kief(Director of Engineering)Marc Jin(Chief Operating Officer)inYuval Somekh(Chief Financial Officer)inAndrew Marecki(EVP of Technology)in

BoardDavid Roberts(Director)

Co-investorsNorwich Ventures

Magellandxmagellandx.com

LeadCare II is a rapid blood test device that identifies lead exposure in children within 3 minutes using a fingerstick sample at the point of care.

Digital HealthHealthtechMedical Devices

Magritekmagritek.com in 𝕏

Magritek develops benchtop NMR spectrometers and related hardware for chemistry laboratories and research applications, enabling on-line monitoring of chemical reactions and analysis.

Advanced ManufacturingDeep TechHardwareNew MaterialsWellington, NZ

Professor Sir Paul T. Callaghan(Founding Inventor)Bernhard Blümich(Director)Juan Perlo(Co-CEO Magritek GmbH)inFederico Casanova(Director and Group CEO Magritek)in

Co-investorsRangatira Investments

Meadowhawk Biolabsmeadowhawkbiolabs.com in

BiotechMarlborough, US

Peter Glick(Executive Officer, Director)inJames Jersey(Executive Officer, Director)Jessica Sullivan(Executive Officer)inGlick Peter(Executive Officer, Director)

BoardHerbert Hooper(Director)

Medpharmmedpharm.com in

MedPharm is a contract development and manufacturing organization (CDMO) focused on topical, transdermal, and transepithelial drug products, supporting formulation development, in vitro testing, and GMP manufacturing from early development through commercial supply.

Advanced ManufacturingBiotechHealthtechMedical DevicesGuildford, GB

Co-investorsOrbiMed

Mycovetrusmycovetrus.com

NanoImaging Servicesnanoimagingservices.com inJun 2023

Nano Imaging Services is a US-based contract research organization (CRO) with in-house cryo-EM microscopes, providing protein production and cryo-electron microscopy services.

BiotechDeep TechHealthtechSan Diego, US

Bridget Carragher(Director)inClinton S. Potter(Director)John Rigg(Executive Officer, Director)inJanine LeBlanc(Executive Officer)inPeter H. Glick(Executive Officer, Director)inBrian Conkle(Executive Officer)

NeoGenomicsneogenomics.com in 𝕏

NeoGenomics develops diagnostic tests and tools for cancer care, including tests for immunotherapy response monitoring, therapy selection, and minimal residual disease detection.

BiotechDigital HealthHealthtechMedical Devices

Tony Zook(Chief Executive Officer)in

Nexcelomnexcelom.com

Novaquestnovaquest.com

NuvinkaDx

P 95p-95.com in

P95 is a clinical research and pharmaceutical services company that supports pharmaceutical development through medical monitoring, epidemiology, biostatistics, study management, pharmacovigilance, and medical writing services.

BiotechData & InfrastructureDigital HealthHealthtechMedical DevicesLeuven, BE

Bassem Saleh(Chief Executive Officer)

Patheonpatheon.com in 𝕏

Patheon, part of Thermo Fisher Scientific, is a contract development and manufacturing organization (CDMO) that also offers clinical research (CRO) services for biotechnology and pharmaceutical sponsors.

Advanced ManufacturingBiotechHealthtech

Co-investorsFrazier Healthcare Partners

Phosphorexphosphorex.com

PHTclario.com in 𝕏Acquired

Clario provides clinical trial technology and data management services, including endpoint and evidence-generation solutions for site-based, decentralized, and hybrid trials.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSaaS

Co-investorsRho Ventures

PPSprotagene.com in

ProtaGene provides molecular bioanalytical services for gene therapy development, specializing in biodistribution studies, transgene expression assessment, and vector shedding analysis to support preclinical safety evaluation and clinical development of viral vector-based therapies.

BiotechDeep TechEnterprise SoftwareMedical DevicesBurlington, US

Michael Stump(President, US)Roland Moussa(President, EU)inTina Gerhards(Vice President, Quality Management)inAndré Abts(Vice President, Project Management CMC)inJulian Stendler(Vice President, IT)inPetra Weingarten(Vice President, Human Resources)

Co-investorsD11Z

Precisioncoatingprecisioncoating.com in

Precision Coating provides surface modification and coating services for medical devices, wires, and instruments.

Advanced ManufacturingEnterprise SoftwareMedical DevicesNew MaterialsHudson, US

Purnapurna.be

Purna provides contract development and manufacturing services for pharmaceutical projects, focusing on long-term customer partnerships and operational flexibility to meet customized client needs.

Advanced ManufacturingBiotechHealthtechBelgium, BE

Recipharmrecipharm.com

Resolianresolian.com in

Resolian is a Contract Research Organization (CRO) that provides bioanalytical, biomarker, and analytical sciences services to support drug development for pharma and biotech companies.

BiotechDeep TechHealthtechMedical Devices

Specac’sspecac.com in 𝕏

Specac designs and manufactures accessories and sample preparation solutions for spectroscopy applications including FTIR, XRF, and NIR, serving customers in academia, manufacturing, and diagnostics globally.

Advanced ManufacturingDeep TechEdTechHardwareNew MaterialsLondon, GB

Stan RansonBernard Hawker

Co-investorsForesight Group

Stagebiostagebio.com

Syftgetsyft.app in 𝕏Mar 2022 · $23M

Syft automates multi-channel lead activation by triggering personalized campaigns across email, LinkedIn, Slack, and advertising the moment a qualified prospect is identified.

AdTechData & InfrastructureMarketing TechSaaSSales Tech

Co-investorsAscend Venture Capital

Syft Technologiessyft.com

Syft develops SIFT-MS instruments that perform real-time, chromatography-free trace gas analysis of a broad range of volatile compounds, measuring multiple analytes such as benzene, formaldehyde, and hydrogen sulfide in a single run.

CleantechDeep TechHardware

Co-investorsCure Kids Ventures

Tjoapacktjoapack.com in 𝕏

Tjoapack provides contract packaging services for pharmaceutical companies, handling packaging and supply chain delivery of drug products to patients.

Advanced ManufacturingHealthtechLogistics & Supply Chain

Vantagemedtechvantagemedtech.com

Vernal Biosciencesvernal.bio in 𝕏Apr 2021

Vernal Biosciences is an mRNA contract development and manufacturing organization (CDMO) that produces high-quality mRNA for research and therapeutic development.

Advanced ManufacturingBiotechDeep TechMedical DevicesColchester, US

Christian Cobaugh(Chief Scientific Officer and Founder)in

BoardErrik Anderson(Director)

Co-investorsDynamk Capital Avant Bio

Vibalogics

Vivebiotechvivebiotech.com in

VIVEbiotech is a contract development and manufacturing organization (CDMO) specialized exclusively in lentiviral vectors for both ex vivo and in vivo administration, following EMA and FDA regulatory requirements.

Advanced ManufacturingBiotechMedical Devices

Vueliovuelio.co.uk

Exits · 2

IPOs and acquisitions across the tracked portfolio

ANI PharmaceuticalsNASDAQ: ANIPPerkinelmerNYSE: RVTY

Portfolio news

latest coverage across their companies

Xero Stock And 2 AI Software Picks For Long Term Growth

Syft · finance.yahoo.com · Aug 26, 2026

Quartz Partners LLC Makes New $1.61 Million Investment in ANI Pharmaceuticals, Inc. $ANIP

ANI Pharmaceuticals · marketbeat.com · Aug 20, 2026

PPS Board member raises TIF concerns at city council meeting

PPS · yahoo.com · Aug 12, 2026

PHT Investment Group Launches $500 Million Inaugural Fund to Modernize the Fresh Post-Harvest Produce Supply Chain

PHT · prnewswire.com · Aug 22, 2025

Fund performance · per public LP disclosures · 4

as of Mar 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
Ampersand CF, L.P.LPs: Los Angeles County Employees Retirement Association	2020	—	29.5%	1.78x	1.06x
Ampersand 2011LPs: New York City Employees' Retirement System, Teachers' Retirement System of the City of New York, New York City Police Pension Fund +1 more	2011	—	21.8%	3.24x	3.24x
AmpersandLPs: North Carolina Retirement Systems	2006	—	16.6%	3.12x	3.12x
Ampersand 2006LPs: New York City Employees' Retirement System, Teachers' Retirement System of the City of New York	2006	—	16.9%	3.12x	3.12x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

How many investments has Ampersand made?: Ampersand has 69 tracked investments, 3 of which have exited via acquisition or IPO, including 1 dated in the last 24 months.
What stage does Ampersand invest at?: Ampersand invests at the Growth stage.
What sectors does Ampersand focus on?: Ampersand focuses on Biotech, Healthtech, Medical Devices.
Where is Ampersand located?: Ampersand is headquartered in Boston, US.
Who does Ampersand co-invest with?: Ampersand most often shares deals with ARCH Venture Partners, BioGenerator Ventures, Blumberg Capital, among 34 tracked co-investors.

Images

Similar investors

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

Granatus Ventures

Granatus Ventures is a venture capital firm that backs startups worldwide leveraging Armenia's potential as an emerging technology hub.

$100K – $4.7M

Sofinnova Ventures

Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.

$100K – $15M

Cardinal Partners

Cardinal Partners is a venture capital firm founded in 1996 that invests in healthcare technology-enabled services and life sciences companies, typically as the first institutional investor and sometimes as a co-founder.

Lightstone Ventures

Lightstone Ventures is a life sciences venture firm founded in 2012 that invests in biotech and medtech companies, backing founders translating scientific breakthroughs into therapies and medical technologies.